The Hidden Threat of Strongyloidiasis: A Global Concern
Learn about strongyloidiasis and its impact on health worldwide.
Adama Kazienga, Luc E. Coffeng, Sara Roose, Sake de Vlas, Dora Buonfrate, Salvatore Scarso, Francesca Tamarozzi, Bruno Levecke
― 7 min read
Table of Contents
- What Is Strongyloidiasis?
- How Do You Get It?
- Why Should We Care?
- The WHO's Roadmap
- Treatment Options
- How Do We Know If It's a Problem?
- Need for Better Diagnostics
- What Makes a Good Test?
- Exploring Survey Design
- Understanding Test Performance
- Budget Constraints
- The Importance of Specificity
- The Advantage of Serological Tests
- Comparing Existing Tests
- Finding Cost-Effective Solutions
- Test Performance Requirements
- The Role of Sample Throughput
- The LFA vs. Other Tests
- Survey Designs for Better Control
- Tackling Cost with Innovation
- Conclusion: The Path Ahead
- Original Source
Strongyloidiasis is a disease caused by a tiny worm called Strongyloides Stercoralis. This little guy can sneak into the skin of humans when they come into contact with contaminated soil. It's kind of like getting a surprise visitor, but instead of bringing snacks, this visitor brings a parasite that can lead to some serious health issues.
What Is Strongyloidiasis?
Strongyloidiasis is one of the 21 neglected tropical diseases (NTDs) recognized by the World Health Organization (WHO). These diseases often get overlooked, even though they affect millions of people, especially in tropical and subtropical regions. The worm is good at hiding, infecting around 600 million people worldwide without many noticing.
How Do You Get It?
You can catch strongyloidiasis when your skin touches soil that's been contaminated with the larvae of the worm. This is especially common in areas where sanitation practices are not great, making it easy for the larvae to thrive in the soil.
Why Should We Care?
Even if it's a little worm, strongyloidiasis can lead to big problems. Some people experience mild symptoms, but in others, it can become serious, especially if the immune system is weakened. Given its widespread impact, efforts are underway to tackle this infection.
The WHO's Roadmap
To combat the issue, the WHO has now added strongyloidiasis to its 2020-2030 roadmap for tackling neglected tropical diseases. This is like putting the infection on the to-do list of global health leaders. The goal? To set up effective control programs for communities affected by the disease.
Treatment Options
To help control strongyloidiasis, the WHO recommends giving a single dose of a medication called Ivermectin to entire communities in affected areas. This occurs when the number of people infected is high enough to warrant such action. It's kind of like handing out candy during Halloween, but instead, it's a treatment to help keep everyone safe.
How Do We Know If It's a Problem?
Health experts use surveys to find out how many people are infected with the worm. If the number of infected people is high in a community-about 10% or more-it's time to take action. There are specific methods to check for the larvae in stool samples, but when serology tests are used, the threshold is even higher.
Need for Better Diagnostics
One major issue in fighting this worm is the need for better, more affordable tests to detect it. Current methods might not always be reliable, and new diagnostics that can easily monitor infections in communities are necessary. It's a bit like trying to find your lost sock in a big pile of laundry; you need the right tools to make the search easier.
What Makes a Good Test?
To successfully pinpoint strongyloidiasis cases, new diagnostic tests should meet certain criteria. These requirements include accuracy, speed, and cost-effectiveness. If a test can quickly and correctly tell if someone has the infection without costing an arm and a leg, that's a win-win!
Exploring Survey Design
When it comes to testing for strongyloidiasis, how we set up our surveys is crucial. The design of these surveys can largely impact how effective we are at identifying and treating those infected. Smart planning means we can save time and money while making sure the right people get tested.
Understanding Test Performance
When testing for strongyloidiasis, we want tests to pick up positive cases accurately. We look at things like Sensitivity (how well a test identifies those with the disease) and Specificity (how well it identifies those without it). Ideally, we want both high. If a test is too sensitive, it might flag too many healthy people; if it's not sensitive enough, it could miss those who actually have the infection.
Budget Constraints
A big part of the challenge is doing all this within a budget. If testing costs too much, it won't be feasible, no matter how good the test is. This is where smart planning and innovative testing methods come into play. The goal is to strike a balance between quality testing and managing costs effectively.
The Importance of Specificity
Specificity is particularly important when developing new tests. If the test gets it wrong too often-by flagging healthy people-it can lead to unnecessary worry and wasted resources. So, we want our tests to be specific enough to avoid such situations.
The Advantage of Serological Tests
Serological tests use blood samples to detect antibodies related to the worm. These can be useful because they can reveal past infections. However, like any test, they have to be accurate and cost-effective to be useful on a broad, community level.
Comparing Existing Tests
When looking for the best approaches, comparisons between different tests are essential. Some current tests are more expensive and require more effort than others. For example, the Baermann method is often a go-to for detecting strongyloidiasis, but it can come with a hefty price tag and demands skilled technicians to be effective. In contrast, newer methods, like the lateral flow assay, can be cheaper and easier to use.
Finding Cost-Effective Solutions
A big part of tackling strongyloidiasis is figuring out how to do it without breaking the bank. The ideal solution is one that combines affordability with accuracy. Some tests may be less costly but lack the sensitivity needed for reliable results. Others may be great at detecting the infection but come with a high price tag.
Test Performance Requirements
Depending on the risk of making wrong decisions during testing, requirements for test performance can vary. Generally, tests should aim for high specificity and sensitivity, but exact figures can change based on the community's needs. When designing testing programs, officials have to account for these variables.
The Role of Sample Throughput
When determining how many people can be tested in a given time, throughput matters. A test that can handle more samples per hour means more people can be screened quickly. If a test takes too long, it can slow down the process and thwart control efforts.
The LFA vs. Other Tests
The lateral flow assay, or LFA, is becoming increasingly popular in the fight against strongyloidiasis. It’s cheaper and can provide quick results, making it ideal for situations where time and money are tight. On the flip side, the Baermann method, while reliable, can be cost-prohibitive and requires skilled professionals, which can be a barrier in resource-limited settings.
Survey Designs for Better Control
When planning surveys, it’s essential to know how many schools to test and how many children to sample. The right balance will ensure that the survey is thorough without becoming too costly. Testing across different schools can help provide a more accurate picture of the infection spread.
Tackling Cost with Innovation
Finding innovative approaches to testing can significantly lower costs. For instance, if testing for multiple diseases using the same sample, the costs can be spread out, making it easier to manage budgets while still keeping an eye on various health threats.
Conclusion: The Path Ahead
In conclusion, fighting strongyloidiasis effectively requires smart planning around testing strategies. As we explore new diagnostic methods, remember that the ultimate goal is to improve health outcomes while remaining cost-effective. By focusing on developing user-friendly tests and efficient survey designs, we'll be better equipped to tackle this sneaky worm and improve the lives of those affected. Now, let’s get to work and start gathering those samples-after all, no one wants to deal with the unwanted visit from a parasitic worm!
Title: Target product profiles for new diagnostics to inform strongyloidiasis control programs
Abstract: BackgroundThe World Health Organization calls for the development of new diagnostics to support large-scale deworming programs against strongyloidiasis. To better steer research and development (R&D) of new diagnostics, it is imperative to identify the minimal requirements that new diagnostics should meet, the so-called target product profiles (TPPs). While diagnostic TPPs exist for other major soil-transmitted helminthiases, none exist for strongyloidiasis. MethodsWe investigated a range of potential diagnostic TPPs using our previously developed simulation framework for the effect of imperfect diagnostics on the cost and correctness of program decisions. With this framework, we studied the minimum requirements for diagnostic performance, cost per test and sample throughput for future assays while comparing the survey costs with those of the reference Baermann method. As potential assay platforms, we considered antibody (Ab)-detecting assays, including a point-of-care lateral flow assay (LFA) and a laboratory-based Ab-ELISA. We also determined cost-efficient school-based survey designs for two currently available assays: Bordier Ab-ELISA and a prototype NIE-LFA. Principal findingsOur findings highlighted that (i) specificity rather than sensitivity is a critical parameter to consider for R&D of new diagnostic methods for monitoring control programs; (ii) the requirements for diagnostic performance became less stringent with an increasing sample size and when higher risks of incorrect decision-making were accepted. When focusing on the assay formats, the LFA resulted in lower survey costs compared to the Baermann method. Ab-ELISA was cost-efficient only if the diagnostic performance was nearly perfect combined with low cost per test and high sample throughput. Of all the three assays considered here, the prototype NIE-LFA allowed for the most cost-efficient survey designs. Conclusion/significanceR&D should focus on developing point-of-care assays with high specificity. The prototype NIE-LFA is a cost-efficient alternative to Baermann to support control programs for strongyloidiasis. Author summaryThe World Health Organization calls for the development of rapid, easy-to-use, and performant point-of-care diagnostics to follow up large-scale deworming programs against strongyloidiasis. However, there are no further recommendations regarding the required performance and cost of such new diagnostics. We performed a simulation study and a cost analysis to assess the minimum requirements in terms of diagnostic sensitivity and specificity, cost per test, and sample throughput for future assays while comparing the survey costs with those of a reference method. In addition, we determined the most cost-efficient survey designs to support control programs for strongyloidiasis applying currently available assays. Our results indicate that research & development efforts should focus on developing point-of-care assays with high specificity. Of the currently available diagnostics, a prototype of a rapid diagnostic test resulted in the lowest total survey cost, while restricting the risk of incorrect policy decisions to the minimum.
Authors: Adama Kazienga, Luc E. Coffeng, Sara Roose, Sake de Vlas, Dora Buonfrate, Salvatore Scarso, Francesca Tamarozzi, Bruno Levecke
Last Update: 2024-12-13 00:00:00
Language: English
Source URL: https://www.medrxiv.org/content/10.1101/2024.12.12.24318904
Source PDF: https://www.medrxiv.org/content/10.1101/2024.12.12.24318904.full.pdf
Licence: https://creativecommons.org/licenses/by/4.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to medrxiv for use of its open access interoperability.